Tag: alcohol use disorder

From Alcohol to Gambling, Lyra Data Show Escapist Behaviours Climb amid Sustained Stress

Photo by Niek Doup on Unsplash

Lyra Southern Africa’s latest behavioural health data reveals a steady year‑on‑year rise in addictive behaviours among South African employees, reflecting how prolonged stress is reshaping the ways people cope, escape and self‑manage emotional pressure.

Drawn from a five‑year analysis of Employee Wellness Programme trends, the data shows total addictive behaviour cases increasing from 1.79 percent of all cases in 2021 to 2.85 percent in 2025. While this may appear modest when viewed only as a percentage point shift, it in fact represents close to 60 percent growth over the period. Clinicians caution that this scale of increase reflects a material change in coping patterns, unfolding alongside heightened financial, social and psychological strain.

“This is not about sudden spikes or isolated events,” says Dubekile Mugumbate, Business Intelligence and Consulting Manager at Lyra Southern Africa. “It’s about stress that has become part of everyday life, and the coping strategies people reach for when that stress doesn’t let up.”

Lyra’s clinicians note that addictive behaviours rarely appear in isolation. They are often intertwined with anxiety, burnout, relationship strain and overwhelming life pressure. In the current climate, marked by economic uncertainty, rising living costs and ongoing instability at both household and societal levels, more people are turning to behaviours that offer short‑term relief or distraction.

Alcohol remains the most prevalent addictive behaviour across all five years, showing consistent year‑on‑year growth. Alcohol‑related cases have nearly doubled over the period, rising from just over 1 percent of all cases in 2021 to slightly above 2 percent in 2025. Clinicians describe this as a familiar pattern in high‑stress environments, where alcohol becomes an accessible and socially acceptable form of escape from relentless pressure. “When pressure is constant, people reach for what’s available and what works quickly to ‘numb the pain’,” Mugumbate explains.

Drug‑related cases present a different picture. While still significant, drug use and misuse shows a gradual decline as a proportion of addictive behaviour cases over the same period. This does not signal reduced risk, but rather changing access and preference as people gravitate toward behaviours that feel easier to hide or justify in daily life.

Gambling shows one of the sharpest increases. Though starting from a low base, gambling‑related cases more than quadrupled in the data set between 2021 and 2025. Clinicians link this rise to the normalisation of online betting platforms, instant gratification mechanics and the false sense of control gambling can offer to people feeling powerless in other areas of their lives.

Pornography use and sex‑related addictions remain smaller categories overall, but they continue to surface consistently year after year. These behaviours are often framed by employees not as addiction at first, but as stress relief, boredom management or emotional escape. Over time, however, they frequently intersect with shame, relationship breakdown and emotional withdrawal.

Internet and social media addiction, while still representing a smaller proportion of cases, shows renewed growth in 2025 after earlier fluctuations. Lyra clinicians note that constant digital engagement offers immediate distraction, connection and numbing, particularly during periods of uncertainty, loneliness or emotional overload.

Generational insights reveal important differences in how addictive behaviours manifest. Gen Y continues to represent the largest share of cases across all five years. This group consistently accounts for around a third of addictive behaviour presentations, reflecting the compounded pressures of mid‑career responsibility, financial obligation, dependants and expectation overload. For many, escapist behaviours become a way to briefly step away from relentless demand.

“For many Gen Y employees, the load never really comes off,” says Mugumbate. “Escapist behaviours can become the only space where the system pauses, even briefly.”

Gen Z follows closely behind, with a notable dip and resurgence over the period. Clinicians working with younger employees describe a generation navigating early career insecurity, limited disposable income and high exposure to digital environments that reward compulsive engagement.

Gen X shows steady growth year on year, particularly in the later years of the data. Here, addictive behaviours often emerge alongside cumulative burnout, long‑term stress and emotional fatigue rather than risk‑taking alone.

Gen Alpha presentations remain small but concerning. Drug use and pornography are more pronounced within this group than might be expected, highlighting early exposure, digital accessibility and the role of unmonitored online spaces. Clinicians stress the importance of early intervention as these patterns form at younger ages.

Baby Boomers make up a small proportion of cases but tend to present later and with more entrenched patterns. When addictive behaviours do surface in this group, they often intersect with grief, retirement‑related identity loss, health challenges or financial anxiety.

Across all generations, the common thread is escapism. Each behaviour offers momentary relief from stress, whether through numbing, distraction, stimulation or perceived control. In a high‑stress environment, those short breaks can become coping habits, and habits can harden into dependency.

“The rise we’re seeing in addictive behaviours is closely linked to the sustained pressure South Africans have been living under for several years now,” says Mugumbate. “When stress becomes chronic, people don’t always look for long‑term solutions. They look for immediate relief, and that’s where these behaviours come in.”

She adds that organisations often underestimate how closely stress, mental health and addictive behaviours are connected in the workplace.

“Addictive behaviour is rarely about the behaviour alone it’s a signal that something deeper is going unmet. In the current environment, many employees feel overwhelmed, financially stretched and emotionally depleted. Employers who want to protect productivity and wellbeing need to understand that prevention, early support and open conversation are far more effective than waiting until patterns become entrenched.”

As economic pressure, uncertainty and emotional fatigue continue to define daily life for many South Africans, the data suggests that addictive behaviours will remain a growing risk where people are left to cope alone. Organisations that recognise these patterns and invest in accessible, stigma‑free support play a critical role in helping employees find healthier ways to manage the weight they are carrying.

Ketamine High not Why Treatment Works for Acohol Use Disorder, Study Finds

Photo by Bruce Christianson on Unsplash

The psychedelic effects recreational users often seek from taking ketamine do not predict the therapeutic benefits for people being treated for alcohol use disorder, according to new research from King’s College London and University of Exeter.

The popular theory, which says that ketamine may have its therapeutic benefits because it produces strong psychedelic effects, has been called into question by the new study, published in Addiction. The findings suggest the treatment response may be down to other effects of the drug. 

The research, led by the Institute of Psychiatry, Psychology & Neuroscience at King’s, is the largest randomised controlled trial to date examining the use of intravenous ketamine-assisted psychotherapy for individuals with moderate to severe alcohol use disorder. It uses data from the Ketamine for reduction of Alcoholic Relapse (KARE) clinical trial at the University of Exeter and University College London.

For the first time, we thoroughly investigated the acute psychoactive effects of repeated ketamine infusions in people with alcohol use disorder. The effects didn’t predict ketamine’s therapeutic benefit, which leaves open other psychological or neural mechanisms that need to be investigated.

Dr Will Lawn, Senior Lecturer at King’s College London and study lead

Researchers carried out a secondary analysis of the KARE clinical trial which was conducted at two clinical research facilities in England involving 96 adult participants and sought to clarify the role of ketamine’s psychoactive effects in supporting abstinence from alcohol. 

Participants receiving three weekly infusions of intravenous ketamine reported marked psychoactive experiences, including altered reality, out-of-body sensations, and perceptual distortions, compared to those receiving placebo. These effects were consistently strong across all three dosing sessions. This suggests little to no development of tolerance to ketamine’s subjective effects over the short dosing schedule.

But despite the pronounced psychoactive effects, the study found no significant evidence that these experiences mediated ketamine’s therapeutic benefit in reducing alcohol consumption. The percentage of days abstinent from alcohol over six months was not predicted by the intensity of subjective drug effects.

A larger trial will explore ketamine’s effects in brain connection and function changes, as well as dosing.

Source: King’s College London

Repurposed Anti-inflammatory Drug may Help Treat Pain from Alcohol Use Disorder

Photo from Pixabay CC0

A Scripps Research study has found that a drug already FDA-approved for treating inflammatory conditions may help reduce both alcohol intake and pain sensitivity in alcohol use disorder (AUD).

The results, published in JCI Insight, suggest that the drug apremilast, a phosphodiesterase-4 (PDE4) inhibitor, or a compound that blocks an enzyme involved in inflammation, could be repurposed as a dual-acting therapy for AUD, particularly in individuals who have pain during and after alcohol use.

AUD affects an estimated 400 million people aged 15 years or older, according to the World Health Organization. Chronic pain is one of the strongest predictors of alcohol relapse, yet it’s often overlooked in AUD treatment strategies. People with AUD frequently experience mechanical allodynia as well, a condition in which even light touch is perceived as painful. This sensitivity can persist during abstinence and contribute to ongoing alcohol use and relapse.

“Our findings highlight the therapeutic value of apremilast to reduce co-occurring drinking and mechanical allodynia in long-term abstinence – a critical component of harmful drinking and AUD psychopathology,” says senior author Marisa Roberto, a professor of neuroscience at Scripps Research.

Currently FDA-approved for treating psoriasis (a chronic autoimmune skin condition) and psoriatic arthritis (a related joint disease), apremilast has previously been shown to reduce alcohol drinking in both mice and humans. The new study builds on that work by examining whether apremilast could also ease pain linked to alcohol exposure.

To investigate, the research team tested apremilast in a type of rat genetically predisposed to higher alcohol consumption and in a standard genetic strain of rats. Both rat strains were given access to alcohol and treated with either apremilast or a placebo.

Apremilast significantly reduced alcohol intake across strains and biological sexes. It also decreased pain sensitivity in most groups, both immediately after drinking and during abstinence, ranging from 24 hours to four weeks after alcohol had been removed.

“But at specific time points, the patterns of reduction differed between males and females, as well as between strains,” notes first author Bryan Cruz, a postdoctoral fellow at Scripps Research. For example, the pain-relieving effects of apremilast weren’t observed in some of the male rats, underscoring the importance of considering biological sex in future studies.

In another set of experiments, apremilast increased GABAergic transmission. a type of inhibitory signaling that helps regulate pain and stress signalling, in the central amygdala, which is involved in both addiction and pain. This effect was only observed in the standard strain of rats, suggesting that apremilast’s impact on brain signalling may depend on genetic background or vulnerability to AUD.

In both strains of male rats, alcohol exposure increased expression of PDE4 genes in the brain, further supporting a link between inflammation, pain and compulsive alcohol use. While other PDE4 inhibitors have been studied for pain unrelated to alcohol consumption, apremilast may offer a path toward more personalized therapies for those with both AUD and pain. But clinical research is still needed to determine the drug’s efficacy for such conditions in humans.

Going forward, the researchers also plan to explore whether apremilast can mitigate anxiety and other negative emotional states that commonly emerge during alcohol withdrawal.

“For over a decade, it’s been well-established that withdrawal-induced anxiety is a major driver of relapse,” points out Roberto. “Therefore, addressing other key components of the addiction cycle is critical, as many individuals use alcohol to cope not only with physical pain but with emotional distress as well.”

Source: Scripps Research Institute